Merck & Company Inc (MRK)vsTriSalus Life Sciences Inc. (TLSI)
MRK
Merck & Company Inc
$112.16
+2.73%
HEALTHCARE · Cap: $274.03B
TLSI
TriSalus Life Sciences Inc.
$4.39
+1.62%
HEALTHCARE · Cap: $275.75M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 143886% more annual revenue ($65.01B vs $45.15M). MRK leads profitability with a 28.1% profit margin vs -86.9%. MRK earns a higher WallStSmart Score of 59/100 (C).
MRK
Buy59
out of 100
Grade: C
TLSI
Avoid25
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-16.2%
Fair Value
$96.56
Current Price
$112.16
$15.60 premium
Margin of Safety
-51.4%
Fair Value
$3.15
Current Price
$4.39
$1.24 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Revenue surging 59.8% year-over-year
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -496.2% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bull Case : TLSI
The strongest argument for TLSI centers on Revenue Growth. Revenue growth of 59.8% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Bear Case : TLSI
The primary concerns for TLSI are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
MRK profiles as a value stock while TLSI is a hypergrowth play — different risk/reward profiles.
TLSI carries more volatility with a beta of 0.54 — expect wider price swings.
TLSI is growing revenue faster at 59.8% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (59/100 vs 25/100), backed by strong 28.1% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →TriSalus Life Sciences Inc.
HEALTHCARE · MEDICAL DEVICES · USA
TriSalus Life Sciences Inc. (TLSI) is an innovative biopharmaceutical company at the forefront of transforming cancer therapy through its proprietary localized drug delivery systems. By optimizing the efficacy of immuno-oncology agents and tackling significant distribution hurdles within the tumor microenvironment, TriSalus aims to enhance therapeutic outcomes for cancer patients. The company boasts a compelling pipeline of clinical programs that underscore its dedication to addressing the pressing need for advanced cancer treatments. With a strategic vision centered on expanding access to these critical therapies, TriSalus is positioned to be a significant player in the evolving oncology sector.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?